Leon Dinshaw

Leon Dinshaw

Auto-generated profile, based on publicly available information

Leon Dinshaw

University Medical Center Hamburg‐Eppendorf

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 June 2022 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
JDJannis Dickow
Jannis Dickow
PKPaulus Kirchhof
Paulus Kirchhof
HHHolly K. Van Houten
Holly K. Van Houten
LSLindsey R. Sangaralingham
Lindsey R. Sangaralingham
LDLeon H. W. Dinshaw
Leon H. W. Dinshaw
XYXiaoxi Yao
Xiaoxi Yao
Background: EAST‐AFNET 4 (Early Treatment of Atrial Fibrillation for Stroke Prevention Trial) demonstrated clinical benefit of early rhythm‐control therapy (ERC) in patients with new‐onset atrial fibrillation (AF) and concomitant cardiovascular conditions compared with current guideline‐based practice. This study aimed to evaluate the generalizability of EAST‐AFNET 4 in routine practice. Methods and Results: Using a US administrative database, we identified 109 739 patients with newly diagnosed AF during the enrollment period of EAST‐AFNET 4. Patients were classified as either receiving ERC, using AF ablation or antiarrhythmic drug therapy, within the first year after AF diagnosis (n=27 106) or not receiving ERC (control group, n=82 633). After propensity score overlap weighting, Cox proportional hazards regression was used to compare groups for the primary composite outcome of all‐cause mortality, stroke, or hospitalization with the diagnoses heart failure or myocardial infarction. Most patients (79 948 of 109 739; 72.9%) met the inclusion criteria for EAST‐AFNET 4. ERC was associated with a reduced risk for the primary composite outcome (hazard ratio [HR], 0.85; 95% CI, 0.75–0.97 [ P =0.02]) with largely consistent results between eligible (HR, 0.89; 95% CI, 0.76–1.04 [ P =0.14]) or ineligible (HR, 0.77; 95% CI, 0.60–0.98 [ P =0.04]) patients for EAST‐AFNET 4 trial inclusion. ERC was associated with lower risk of stroke in the overall cohort and in trial‐eligible patients. Conclusions: This analysis replicates the clinical benefit of ERC seen in EAST‐AFNET 4. The results support adoption of ERC as part of the management of recently diagnosed AF in the United States.

2 February 2021 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
LDLeon Dinshaw
Leon Dinshaw
PMPaula Münkler
Paula Münkler
BSBenjamin Schäffer
Benjamin Schäffer
NKNiklas Klatt
Niklas Klatt
CJChristiane Jungen
Christiane Jungen
CMChristian Meyer
Christian Meyer
Background: Atrial fibrillation (AF) is common in patients with hypertrophic cardiomyopathy (HCM) and is associated with a deterioration of clinical status. Ablation of symptomatic AF is an established therapy, but in HCM, the characteristics of recurrent atrial arrhythmias and the long‐term outcome are uncertain. Methods and Results: Sixty‐five patients with HCM (aged 64.5±9.9 years, 42 [64.6%] men) underwent AF ablation. The ablation strategy included pulmonary vein isolation in all patients and ablation of complex fractionated atrial electrograms or subsequent atrial tachycardias (AT) if appropriate. Paroxysmal, persistent AF, and a primary AT was present in 13 (20.0%), 51 (78.5%), and 1 (1.5%) patients, respectively. Twenty‐five (38.4%) patients developed AT with a total number of 54 ATs. Stable AT was observed in 15 (23.1%) and unstable AT in 10 (15.3%) patients. The mechanism was characterized as a macroreentry in 37 (68.5%), as a localized reentry in 12 (22.2%), a focal mechanism in 1 (1.9%), and not classified in 4 (7.4%) ATs. After 1.9±1.2 ablation procedures and a follow‐up of 48.1±32.5 months, freedom of AF/AT recurrences was demonstrated in 60.0% of patients. No recurrences occurred in 84.6% and 52.9% of patients with paroxysmal and persistent AF, respectively ( P <0.01). Antiarrhythmic drug therapy was maintained in 24 (36.9%) patients. Conclusions: AF ablation in patients with HCM is effective for long‐term rhythm control, and especially patients with paroxysmal AF undergoing pulmonary vein isolation have a good clinical outcome. ATs after AF ablation are frequently observed in HCM. Freedom of atrial arrhythmia is achieved by persistent AF ablation in a reasonable number of patients even though the use of antiarrhythmic drug therapy remains high.

1 April 2023 in Circulation: Arrhythmia and Electrophysiology
Verified
Journal Article
Closed access
MLMarc D Lemoine
Marc D Lemoine
CMCeline Mencke
Celine Mencke
MNMoritz Nies
Moritz Nies
JOJulius Obergassel
Julius Obergassel
KSKatharina Scherschel
Katharina Scherschel
PKPaulus Kirchhof
Paulus Kirchhof

28 February 2019 in Journal of Cardiovascular Electrophysiology
Verified
Journal Article
Closed access
PDF file
LDLeon Dinshaw
Leon Dinshaw
BSBenjamin Schäffer
Benjamin Schäffer
ÖAÖzge Akbulak
Özge Akbulak
MJMario Jularic
Mario Jularic
JHJens Hartmann
Jens Hartmann
CMChristian Meyer
Christian Meyer

1 August 2020 in Circulation: Arrhythmia and Electrophysiology
Verified
Journal Article
Closed access
PDF file
UUUniversitäres Herzzentrum Hamburg (UHZ) am UKE
Universitäres Herzzentrum Hamburg (UHZ) am UKE
Christoph SinningChristoph Sinning
Christoph Sinning
BRBruno Reissmann
Bruno Reissmann
RSRuben Schleberger
Ruben Schleberger
LDLeon Dinshaw
Leon Dinshaw
AMAndreas Metzner
Andreas Metzner

29 November 2025 in EP Europace
Verified
Journal Article
Open access
Francesco SantoroFrancesco Santoro
Francesco Santoro
Giacomo MugnaiGiacomo Mugnai
Giacomo Mugnai
LPLaura Perrotta
Laura Perrotta
BKBoldizsar Kovacs
Boldizsar Kovacs
LDLeon Dinshaw
Leon Dinshaw
KVKevin Vernooy
Kevin Vernooy
Aims: Ventricular tachycardia (VT) in ischaemic heart disease (IHD) requires complex management strategies including catheter ablation (CA) and anti-arrhythmic drugs (AADs). The aim of this study is to compare efficacy and safety of CA vs. AADs in patients with IHD and VT. Methods and results: We performed a meta-analysis of randomized controlled trials (RCTs) enrolling patients with IHD and ICD randomized to CA or AADs. Primary outcome was appropriate ICD therapy. Secondary outcomes included inappropriate ICD therapy, cardiovascular (CV) re-hospitalization, all-cause/CV mortality, and adverse events. Subgroup analyses were conducted for amiodarone and sotalol, with an exploratory evaluation of a composite endpoint (ICD shock, VT storm, all-cause death). Four RCTs including 947 patients (mean age 68 ± 2 years; 93% male) were analysed. CA significantly reduced the risk of appropriate ICD therapy compared with AADs (149/470 [31.7%] vs. 229/477 [48.0%]; RR 0.81; 95% CI [0.67, 0.97]; P = 0.02). Among secondary outcomes, CA decreased the incidence of CV re-hospitalization [RR 0.84; 95% CI (0.72, 0.99); P = 0.04] and adverse events [RR 0.42; 95% CI (0.28, 0.62); P < 0.01], while no differences were observed in all-cause/CV mortality and inappropriate ICD therapy. In subgroup analyses, CA was superior to sotalol in reducing the composite endpoint of ICD shock, VT storm and all-cause death [RR: 0.82, 95% CI (0.69, 0.98), P = 0.03]; whereas, no significant benefit was seen compared to amiodarone [RR: 0.92; 95% CI (0.78, 1.09), P = 0.32]. Conclusion: In ischaemic heart disease and VT, CA compared with anti-arrhythmic drugs is associated with a reduction of appropriate ICD therapy, cardiovascular re-hospitalization, and adverse events with benefits most evident versus sotalol.